STARD7 could be an immunological and prognostic biomarker: from pan-cancer analysis to hepatocellular carcinoma validation
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The STARD7 gene is highly expressed in many cancers, correlating with poor prognosis and impacting tumor immunity. Its suppression hinders cancer cell growth and spread, suggesting STARD7 as a potential biomarker for cancer immunotherapy.
Area Of Science
- Oncology
- Genomics
- Bioinformatics
Background
- Tumor landscape understanding has advanced with sequencing and gene mapping.
- Effective tumor treatment remains challenging, necessitating tumor marker prediction and drug resistance studies.
Purpose Of The Study
- To investigate the prognostic and differential expression of the STARD7 gene in human pan-cancer.
- To explore STARD7's role in tumor immunity and its potential as a diagnostic and prognostic biomarker.
Main Methods
- Comprehensive bioinformatics analysis of STARD7 expression, diagnostics, and prognostic significance.
- Experimental validation in liver cancer using qRT-PCR, CCK8, and transwell assays.
Main Results
- STARD7 is differentially expressed in 25 tumors (high in 22), associated with poor prognosis and diagnosis.
- STARD7 influences the tumor immune microenvironment and its methylation correlates with survival.
- STARD7 suppression impedes hepatocellular carcinoma cell proliferation, migration, and invasion.
Conclusions
- STARD7 shows potential as a prognostic biomarker and correlates with tumor immunity across various cancers.
- Findings support STARD7's role in cancer immunotherapy and precision immuno-oncology.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.